AGAP3 as A Potential Drug Target for Alzheimer's (G116988)

Target Name: AGAP3

NCBI ID: G116988

AGAP3 as A Potential Drug Target for Alzheimer's

AGAP3 (Alzheimer's disease-associated protein 3) is a protein that is expressed in the brain and has been linked to the development and progression of Alzheimer's disease. It is a small protein that is made by the brain and has been shown to be involved in the formation of beta-amyloid plaques, which are a hallmark of Alzheimer's disease.

Recent studies have suggested that AGAP3 may be a drug target or biomarker for the treatment of Alzheimer's disease. This is because AGAP3 has been shown to be involved in the formation of beta-amyloid plaques, which are a major cause of the development and progression of Alzheimer's disease. By targeting AGAP3, researchers may be able to reduce the formation of beta-amyloid plaques and potentially slow down or even reverse the progression of Alzheimer's disease.

One way that AGAP3 may be targeted as a drug is through its role in the formation of beta-amyloid plaques. Researchers have shown that AGAP3 is involved in the formation of beta-amyloid plaques by helping to transport the amino acid LDL (low-density lipoprotein) to the brain. When LDL is introduced to the brain, it can react with a protein called APP (amyloid precursor protein) to form beta-amyloid plaques.

In addition to its role in the formation of beta-amyloid plaques, AGAP3 has also been shown to be involved in the regulation of the immune response. This is important because the immune response is thought to play a role in the development and progression of Alzheimer's disease.

Research has also suggested that AGAP3 may be involved in the regulation of the blood-brain barrier. The blood-brain barrier is a barrier that separates the brain from the blood and helps to protect it from harmful substances. AGAP3 has been shown to be involved in the regulation of the blood-brain barrier, which may be important for the treatment of Alzheimer's disease.

Overall, AGAP3 is a protein that has been linked to the development and progression of Alzheimer's disease. Recent studies have suggested that AGAP3 may be a drug target or biomarker for the treatment of Alzheimer's disease, due to its involvement in the formation of beta-amyloid plaques and its role in the regulation of the immune response and blood-brain barrier. Further research is needed to fully understand the potential role of AGAP3 in the treatment of Alzheimer's disease.

Protein Name: ArfGAP With GTPase Domain, Ankyrin Repeat And PH Domain 3

Functions: GTPase-activating protein for the ADP ribosylation factor family (Potential). GTPase which may be involved in the degradation of expanded polyglutamine proteins through the ubiquitin-proteasome pathway

More Common Targets